Sarepta Therapeutics Inc. shares surged nearly 3% in premarket trade Monday after RBC Capital Markets analyst Matthew Eckler said he sees a “compelling argument” for faster-than-normal approval of Sarepta’s Duchenne muscular dystrophy drug golodirsen. Sarepta recently released positive early/mid-stage clinical trial results for the DMD drug, and presented more data at a conference over the weekend. “Full golodirsen biopsy results look consistent and high-quality; suggest efficacy likely better than Exondys 51,” Eckler said, referring to Sarepta’s DMD drug that was approved last year after an unusual amount of controversy. Sarepta thus has a “compelling argument for engaging FDA on accelerated approval (meeting likely 1Q18), in our view,” Eckler said. Sarepta shares have surged nearly 50% over the last three months, compared with a 5% rise in the S&P 500 .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News